Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer.

Vo DT, Karanam NK, Ding L, Saha D, Yordy JS, Giri U, Heymach JV, Story MD.

Neoplasia. 2019 Sep;21(9):849-862. doi: 10.1016/j.neo.2019.06.004. Epub 2019 Jul 18.

2.

Methodology to reduce 6D patient positional shifts into a 3D linear shift and its verification in frameless stereotactic radiotherapy.

Sarkar B, Ray J, Ganesh T, Manikandan A, Munshi A, Rathinamuthu S, Kaur H, Anbazhagan S, Giri UK, Roy S, Jassal K, Mohanti BK.

Phys Med Biol. 2018 Mar 22;63(7):075004. doi: 10.1088/1361-6560/aab231.

PMID:
29480166
3.

Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study.

Giri U, Martin MG.

Blood Adv. 2017 Apr 6;1(10):615-618. doi: 10.1182/bloodadvances.2016002675. eCollection 2017 Apr 11. No abstract available.

4.

RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.

Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH.

Clin Cancer Res. 2018 Jan 15;24(2):341-350. doi: 10.1158/1078-0432.CCR-17-1455. Epub 2017 Oct 13.

5.

Erratum to: Short tangential arcs in VMAT based breast and chest wall radiotherapy lead to conformity of the breast dose with lesser cardiac and lung doses: a prospective study of breast conservation and mastectomy patients.

Munshi A, Sarkar B, Anbazhagan S, Giri UK, Kaur H, Jassal K, Ganesh T, Mohanti BK.

Australas Phys Eng Sci Med. 2017 Sep;40(3):737. doi: 10.1007/s13246-017-0562-2. No abstract available.

PMID:
28608296
6.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV.

Clin Cancer Res. 2017 Sep 15;23(18):5489-5501. doi: 10.1158/1078-0432.CCR-16-3216. Epub 2017 May 30.

7.

Short tangential arcs in VMAT based breast and chest wall radiotherapy lead to conformity of the breast dose with lesser cardiac and lung doses: a prospective study of breast conservation and mastectomy patients.

Munshi A, Sarkar B, Anbazhagan S, Giri UK, Kaur H, Jassal K, Ganesh T, Kalyan Mohanti B.

Australas Phys Eng Sci Med. 2017 Sep;40(3):729-736. doi: 10.1007/s13246-017-0558-y. Epub 2017 May 18. Erratum in: Australas Phys Eng Sci Med. 2017 Jun 12;:.

PMID:
28523470
8.

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV.

Clin Cancer Res. 2017 Jun 1;23(11):2713-2722. doi: 10.1158/1078-0432.CCR-16-2586. Epub 2017 May 5.

9.

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.

Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.

Oncotarget. 2016 Jul 26;7(30):47998-48010. doi: 10.18632/oncotarget.10332.

10.

Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.

Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV.

Clin Cancer Res. 2016 Sep 15;22(18):4643-50. doi: 10.1158/1078-0432.CCR-15-2785. Epub 2016 Apr 1.

11.

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW.

Mol Ther Nucleic Acids. 2015 Dec 15;4:e270. doi: 10.1038/mtna.2015.47.

12.

Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.

Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM.

Oncotarget. 2016 Jan 5;7(1):565-79. doi: 10.18632/oncotarget.6376.

13.

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.

Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM.

Clin Cancer Res. 2016 Apr 1;22(7):1674-1686. doi: 10.1158/1078-0432.CCR-14-2890. Epub 2015 Nov 23.

14.

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.

Nilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV.

Clin Cancer Res. 2016 Apr 15;22(8):1940-50. doi: 10.1158/1078-0432.CCR-15-1994. Epub 2015 Nov 17.

15.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA.

Clin Cancer Res. 2016 Mar 1;22(5):1103-10. doi: 10.1158/1078-0432.CCR-15-1031. Epub 2015 Oct 7.

16.

8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.

Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ.

PLoS One. 2015 Aug 27;10(8):e0135962. doi: 10.1371/journal.pone.0135962. eCollection 2015.

17.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.

18.

Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O.

Cancer Res. 2015 Apr 1;75(7):1527-36. doi: 10.1158/0008-5472.CAN-14-2735. Epub 2015 Jan 29.

19.

Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.

Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV.

BMC Genomics. 2014 Dec 8;15:1079. doi: 10.1186/1471-2164-15-1079.

20.

Vertebral osteomyelitis in an immunosuppressed patient with rheumatoid arthritis.

Giri U, Thavalathil BC, Varghese R.

BMJ Case Rep. 2014 Nov 19;2014. pii: bcr2014206944. doi: 10.1136/bcr-2014-206944.

21.

A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.

Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV.

J Thorac Oncol. 2014 Jul;9(7):965-73. doi: 10.1097/JTO.0000000000000199.

22.

KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.

Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, Multani AS, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung MC, Heymach JV, Lee MG.

J Clin Invest. 2013 Dec;123(12):5231-46. doi: 10.1172/JCI68642. Epub 2013 Nov 8.

23.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

24.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV.

Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6.

25.

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN.

Clin Cancer Res. 2012 Jan 1;18(1):290-300. doi: 10.1158/1078-0432.CCR-11-2260. Epub 2011 Nov 16.

26.

Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.

Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II.

Cancer Res. 2011 Aug 15;71(16):5512-21. doi: 10.1158/0008-5472.CAN-10-2614. Epub 2011 Jul 1.

27.

DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.

Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, Sturgis EM, Weber RS, Garden AS, Ang KK, Schwartz DL.

Clin Cancer Res. 2011 Apr 1;17(7):2035-43. doi: 10.1158/1078-0432.CCR-10-2641. Epub 2011 Feb 24.

28.

Human lymphoma cells develop resistance to radiation in the presence of astrocytes in vitro.

Koto M, Cho H, Riesterer O, Giri U, Story MD, Ha CS, Raju U.

Anticancer Res. 2011 Jan;31(1):33-8.

PMID:
21273577
29.

Blasted cell line names.

Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR.

Cancer Inform. 2010 Oct 14;9:251-5. doi: 10.4137/CIN.S5613.

30.

Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.

Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U.

Anticancer Res. 2009 Nov;29(11):4409-15.

31.

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.

Riesterer O, Matsumoto F, Wang L, Pickett J, Molkentine D, Giri U, Milas L, Raju U.

Invest New Drugs. 2011 Jun;29(3):514-22. doi: 10.1007/s10637-009-9361-2. Epub 2009 Dec 22.

PMID:
20024691
32.

miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue.

Ramdas L, Giri U, Ashorn CL, Coombes KR, El-Naggar A, Ang KK, Story MD.

Head Neck. 2009 May;31(5):642-54. doi: 10.1002/hed.21017.

33.

Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation.

Giri U, Ashorn CL, Ramdas L, Stivers DN, Coombes K, El-Naggar AK, Ang KK, Story MD.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):670-7. Epub 2005 Nov 10.

PMID:
16289374
34.

Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).

Giri U, Terry NH, Kala SV, Lieberman MW, Story MD.

Cancer Chemother Pharmacol. 2005 Jun;55(6):511-21. Epub 2005 Mar 11.

PMID:
15761769
36.
41.

Novel copper superoxide dismutase mimics and damage mediated by O2.-.

Athar M, Iqbal M, Giri U.

Nutrition. 1995 Sep-Oct;11(5 Suppl):559-63. Review.

PMID:
8748222
42.

Ferric nitrilotriacetate (Fe-NTA) is a potent hepatic tumor promoter and acts through the generation of oxidative stress.

Iqbal M, Giri U, Athar M.

Biochem Biophys Res Commun. 1995 Jul 17;212(2):557-63.

PMID:
7626070
43.

Evidence that in situ generated reactive oxygen species act as a potent stage I tumor promoter in mouse skin.

Giri U, Sharma SD, Abdulla M, Athar M.

Biochem Biophys Res Commun. 1995 Apr 17;209(2):698-705.

PMID:
7733940
44.

Hyperfractionation protects against long-term fibrosis in rat lung.

Giri PG, Kimler BF, Giri UP, Cox GG.

Br J Cancer Suppl. 1986;7:324-6. No abstract available.

45.

Comparison of single, fractionated and hyperfractionated irradiation on the development of normal tissue damage in rat lung.

Giri PG, Kimler BF, Giri UP, Cox GG, Reddy EK.

Int J Radiat Oncol Biol Phys. 1985 Mar;11(3):527-34.

PMID:
3972663

Supplemental Content

Support Center